Production (Stage)
COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -27.08% | 20.10% | 67.89% | 67.89% | -20.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -27.08% | 20.10% | 67.89% | 67.89% | -20.43% |
| Cost of Revenue | -8.33% | -68.47% | 155.13% | 155.13% | -17.47% |
| Gross Profit | -51.00% | 261.08% | 2.76% | 2.76% | -23.91% |
| SG&A Expenses | 76.69% | 555.39% | 149.51% | 149.51% | 46.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.19% | 264.38% | 143.10% | 143.10% | 31.09% |
| Operating Income | -99.39% | -151.70% | -237.07% | -237.07% | -392.93% |
| Income Before Tax | -101.60% | -186.28% | -73.15% | -73.15% | -399.45% |
| Income Tax Expenses | -- | 222.26% | -101.70% | -101.70% | -428.21% |
| Earnings from Continuing Operations | -160.89% | -190.57% | -65.35% | -65.35% | -391.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -160.89% | -190.57% | -65.35% | -65.35% | -391.58% |
| EBIT | -99.39% | -151.70% | -237.07% | -237.07% | -392.93% |
| EBITDA | -126.25% | -144.44% | -349.20% | -349.20% | -16,066.67% |
| EPS Basic | -53.30% | -208.06% | -37.53% | -37.53% | -391.38% |
| Normalized Basic EPS | -18.44% | -151.96% | -44.01% | -44.01% | -399.02% |
| EPS Diluted | -53.30% | -208.15% | -37.53% | -37.53% | -391.38% |
| Normalized Diluted EPS | -18.44% | -151.96% | -44.01% | -44.01% | -399.02% |
| Average Basic Shares Outstanding | 70.20% | -16.19% | 20.22% | 20.22% | 0.05% |
| Average Diluted Shares Outstanding | 70.20% | -16.19% | 20.22% | 20.22% | 0.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |